BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12107840)

  • 1. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon.
    Gogas H; Kefala G; Bafaloukos D; Frangia K; Polyzos A; Pectasides D; Tsoutsos D; Panagiotou P; Ioannovich J; Loukopoulos D
    Br J Cancer; 2002 Jul; 87(2):181-6. PubMed ID: 12107840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon.
    Mellado B; Del Carmen Vela M; Colomer D; Gutierrez L; Castel T; Quintó L; Fontanillas M; Reguart N; Domingo-Domènech JM; Montagut C; Estapé J; Gascón P
    J Clin Oncol; 2002 Oct; 20(19):4032-9. PubMed ID: 12351601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival.
    Aubin F; Chtourou M; Teyssier JR; Laubriet A; Mougin CH; Blanc D; Humbert P
    Melanoma Res; 2000 Apr; 10(2):113-8. PubMed ID: 10803711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma.
    Kunter U; Buer J; Probst M; Duensing S; Dallmann I; Grosse J; Kirchner H; Schluepen EM; Volkenandt M; Ganser A; Atzpodien J
    J Natl Cancer Inst; 1996 May; 88(9):590-4. PubMed ID: 8609659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
    Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Wang HJ; Elashoff RM; Takeuchi H; Umetani N; Hoon DS
    J Clin Oncol; 2005 Nov; 23(31):8057-64. PubMed ID: 16258104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma.
    Hasselmann DO; Rappl G; Rössler M; Ugurel S; Tilgen W; Reinhold U
    Oncol Rep; 2001; 8(1):115-8. PubMed ID: 11115581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course.
    Osella-Abate S; Quaglino P; Savoia P; Leporati C; Comessatti A; Bernengo MG
    Melanoma Res; 2002 Aug; 12(4):325-34. PubMed ID: 12170181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of prognostic importance of reverse-transcriptase polymerase chain reaction detection of circulating messenger RNA in patients with melanoma.
    Ranieri JM; Wagner JD; Wiebke EA; Azuaje R; Smith ML; Wenck S; Daggy J; Coleman JJ
    Plast Reconstr Surg; 2005 Apr; 115(4):1058-63. PubMed ID: 15793446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facts and pitfalls in the detection of tyrosinase mRNA in the blood of melanoma patients by RT-PCR.
    Seiter S; Rappl G; Tilgen W; Ugurel S; Reinhold U
    Recent Results Cancer Res; 2001; 158():105-12. PubMed ID: 11092037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon--comparison with tyrosinase rt-PCR.
    Domingo-Domènech J; Molina R; Castel T; Montagut C; Puig S; Conill C; Martí R; Vera M; Auge JM; Malvehy J; Grau JJ; Gascon P; Mellado B
    Oncology; 2005; 68(4-6):341-9. PubMed ID: 16020961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction.
    Palmieri G; Ascierto PA; Perrone F; Satriano SM; Ottaiano A; Daponte A; Napolitano M; Caracò C; Mozzillo N; Melucci MT; Cossu A; Tanda F; Gallo C; Satriano RA; Castello G
    J Clin Oncol; 2003 Mar; 21(5):767-73. PubMed ID: 12610172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
    Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
    Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).
    Fusi A; Collette S; Busse A; Suciu S; Rietz A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U
    Eur J Cancer; 2009 Dec; 45(18):3189-97. PubMed ID: 19793643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma.
    Schittek B; Bodingbauer Y; Ellwanger U; Blaheta HJ; Garbe C
    Br J Dermatol; 1999 Jul; 141(1):30-6. PubMed ID: 10417512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of tyrosinase mRNA from the blood of melanoma patients.
    Stevens GL; Scheer WD; Levine EA
    Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):293-6. PubMed ID: 8722221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma.
    Schmidt H; Sørensen BS; von der Maase H; Bang C; Agger R; Hokland M; Nexo E
    Melanoma Res; 2002 Dec; 12(6):585-92. PubMed ID: 12459648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group.
    Palmieri G; Strazzullo M; Ascierto PA; Satriano SM; Daponte A; Castello G
    J Clin Oncol; 1999 Jan; 17(1):304-11. PubMed ID: 10458247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients.
    Farthmann B; Eberle J; Krasagakis K; Gstöttner M; Wang N; Bisson S; Orfanos CE
    J Invest Dermatol; 1998 Mar; 110(3):263-7. PubMed ID: 9506446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. gp100 mRNA is more sensitive than tyrosinase mRNA for RT-PCR amplification to detect circulating melanoma cells in peripheral blood of melanoma patients.
    Tsukamoto K; Ueda M; Hirata S; Osada A; Kitamura R; Takahashi T; Ichihashi M; Shimada S
    J Dermatol Sci; 2000 Jun; 23(2):126-31. PubMed ID: 10808130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.